©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Jul 24, 2015; 4(2): 83-91
Published online Jul 24, 2015. doi: 10.5410/wjcu.v4.i2.83
Published online Jul 24, 2015. doi: 10.5410/wjcu.v4.i2.83
Update summarising the conclusions of the international consultation on male lower urinary tract symptoms
Altaf Mangera, Christopher Chapple, Department of Urology Research, Royal Hallamshire Hospital, Sheffield S10 2 JF, United Kingdom
Author contributions: Mangera A and Chapple C contributed equally to this manuscript.
Conflict-of-interest statement: Chapple C has the following conflicts of interest Pfizer, Astellas, Novartis, Tanabe, Sumitomo, UCB, Recordati, Allergan, Schwarz and Pfizer; Mangera A has no conflicts of interest to declare.
Correspondence to: Christopher Chapple, MD, Department of Urology Research, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2 JF, United Kingdom. c.r.chapple@shef.ac.uk
Telephone: +44-114-2712559 Fax: +44-114-2797841
Received: August 5, 2014
Peer-review started: August 6, 2014
First decision: September 28, 2014
Revised: April 23, 2015
Accepted: May 8, 2015
Article in press: May 11, 2015
Published online: July 24, 2015
Processing time: 363 Days and 14.3 Hours
Peer-review started: August 6, 2014
First decision: September 28, 2014
Revised: April 23, 2015
Accepted: May 8, 2015
Article in press: May 11, 2015
Published online: July 24, 2015
Processing time: 363 Days and 14.3 Hours
Core Tip
Core tip: Men with lower urinary tract symptoms (LUTS) should be assessed not only for symptom severity and bother but also for risk of progression. Men with a PSA > 1.4 or a prostate larger than 30 mL should be considered for therapy to reduce prostate volume. With the options for management of men with LUTS also involving antimuscarinics, B3 agonists, phosphodiesterase inhibitors and a plethora or surgical options, a personalised approach is required. This is intended will lead to greatest patient satisfaction and improvement in quality of life.